STAT+: Pharmalittle: We’re reading about upbeat results for a Duchenne drug, Takeda layoffs, and much more

Biogen reported mixed results from a clinical trial for an Alzheimer's disease treatment, while Takeda Pharmaceutical plans to cut about 4,500 jobs as part of a restructuring effort. The Biogen drug, diranersen, reduced levels of tau in patients with early-stage Alzheimer's and slowed cognitive decline. Takeda expects annual savings of over $1.27 billion by fiscal 2028.